Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study
Safety and Efficacy of Once-weekly Subcutaneous and Once-daily Oral NNC0487-0111 in Participants With Type 2 Diabetes - a Dose Finding Study
The study will look at how well different doses of a new medicine called NNC0487-0111 help lower the blood sugar and body weight in people with type 2 diabetes. NNC0487-0111 is a new medicine which cannot be prescribed by doctors but has previously been tested in humans. Participants will either get NNC0487-0111, which is given as tablets or as injections, or placebo. Which treatment the participant get is decided by chance.The study will last for about 43 weeks.
Inclusion Criteria:
Exclusion Criteria:
Kyustendil, 2500, Bulgaria
Krapinske Toplice, 49217, Croatia
Goudi/Athens, 11527, Greece
Thessaloniki, 564 29, Greece
Chiba-shi, Chiba, 260-0804, Japan
Ruda Śląska, Gornoslaskie 41-709, Poland
Legnica, Lower Silesian Voivodeship 59-220, Poland
Legnica, Lower Silesian Voivodeship 59-220, Poland
Ruda Śląska, 41-709, Poland
Lodz, Łódź Voivodeship 90-302, Poland
Bucharest, Bucharest 020475, Romania
Bucharest, Bucurestii 020475, Romania